BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 29123154)

  • 1. Modification of single-nucleotide polymorphism in a fully humanized CYP3A mouse by genome editing technology.
    Abe S; Kobayashi K; Oji A; Sakuma T; Kazuki K; Takehara S; Nakamura K; Okada A; Tsukazaki Y; Senda N; Honma K; Yamamoto T; Ikawa M; Chiba K; Oshimura M; Kazuki Y
    Sci Rep; 2017 Nov; 7(1):15189. PubMed ID: 29123154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test.
    Oneda B; Crettol S; Jaquenoud Sirot E; Bochud M; Ansermot N; Eap CB
    Pharmacogenet Genomics; 2009 Nov; 19(11):877-83. PubMed ID: 19801957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Humanized UGT2 and CYP3A transchromosomic rats for improved prediction of human drug metabolism.
    Kazuki Y; Kobayashi K; Hirabayashi M; Abe S; Kajitani N; Kazuki K; Takehara S; Takiguchi M; Satoh D; Kuze J; Sakuma T; Kaneko T; Mashimo T; Osamura M; Hashimoto M; Wakatsuki R; Hirashima R; Fujiwara R; Deguchi T; Kurihara A; Tsukazaki Y; Senda N; Yamamoto T; Scheer N; Oshimura M
    Proc Natl Acad Sci U S A; 2019 Feb; 116(8):3072-3081. PubMed ID: 30718425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trans-chromosomic mice containing a human CYP3A cluster for prediction of xenobiotic metabolism in humans.
    Kazuki Y; Kobayashi K; Aueviriyavit S; Oshima T; Kuroiwa Y; Tsukazaki Y; Senda N; Kawakami H; Ohtsuki S; Abe S; Takiguchi M; Hoshiya H; Kajitani N; Takehara S; Kubo K; Terasaki T; Chiba K; Tomizuka K; Oshimura M
    Hum Mol Genet; 2013 Feb; 22(3):578-92. PubMed ID: 23125282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients.
    Deininger KM; Vu A; Page RL; Ambardekar AV; Lindenfeld J; Aquilante CL
    Clin Transplant; 2016 Sep; 30(9):1074-81. PubMed ID: 27314545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.
    Staatz CE; Goodman LK; Tett SE
    Clin Pharmacokinet; 2010 Apr; 49(4):207-21. PubMed ID: 20214406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients.
    Shi Y; Li Y; Tang J; Zhang J; Zou Y; Cai B; Wang L
    Gene; 2013 Jan; 512(2):226-31. PubMed ID: 23107770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functionally defective or altered CYP3A4 and CYP3A5 single nucleotide polymorphisms and their detection with genotyping tests.
    Lee SJ; Goldstein JA
    Pharmacogenomics; 2005 Jun; 6(4):357-71. PubMed ID: 16004554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statin regulation of CYP3A4 and CYP3A5 expression.
    Willrich MA; Hirata MH; Hirata RD
    Pharmacogenomics; 2009 Jun; 10(6):1017-24. PubMed ID: 19530969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of single-nucleotide polymorphisms (SNPs) in human CYP3A4 and CYP3A5 genes: potential implications for the metabolism of HIV drugs.
    Berno G; Zaccarelli M; Gori C; Tempestilli M; Antinori A; Perno CF; Pucillo LP; D'Arrigo R
    BMC Med Genet; 2014 Jul; 15():76. PubMed ID: 24986243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA.
    Koch I; Weil R; Wolbold R; Brockmöller J; Hustert E; Burk O; Nuessler A; Neuhaus P; Eichelbaum M; Zanger U; Wojnowski L
    Drug Metab Dispos; 2002 Oct; 30(10):1108-14. PubMed ID: 12228187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allele and genotype frequencies of CYP3A4, CYP3A5, CYP3A7, and GSTP1 gene polymorphisms among mainland Tibetan, Mongolian, Uyghur, and Han Chinese populations.
    Qi G; Han C; Zhou Y; Wang X
    Clin Exp Pharmacol Physiol; 2022 Feb; 49(2):219-227. PubMed ID: 34689350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vincristine Disposition and Neurotoxicity Are Unchanged in Humanized CYP3A5 Mice.
    Li Y; Kazuki Y; Drabison T; Kobayashi K; Fujita KI; Xu Y; Jin Y; Ahmed E; Li J; Eisenmann ED; Baker SD; Cavaletti G; Sparreboom A; Hu S
    Drug Metab Dispos; 2024 Jan; 52(2):80-85. PubMed ID: 38071551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors influencing midazolam hydroxylation activity in human liver microsomes.
    He P; Court MH; Greenblatt DJ; von Moltke LL
    Drug Metab Dispos; 2006 Jul; 34(7):1198-207. PubMed ID: 16638818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The genetic determinants of the CYP3A5 polymorphism.
    Hustert E; Haberl M; Burk O; Wolbold R; He YQ; Klein K; Nuessler AC; Neuhaus P; Klattig J; Eiselt R; Koch I; Zibat A; Brockmöller J; Halpert JR; Zanger UM; Wojnowski L
    Pharmacogenetics; 2001 Dec; 11(9):773-9. PubMed ID: 11740341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combinations of chromosome transfer and genome editing for the development of cell/animal models of human disease and humanized animal models.
    Uno N; Abe S; Oshimura M; Kazuki Y
    J Hum Genet; 2018 Feb; 63(2):145-156. PubMed ID: 29180645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea.
    Jun KR; Lee W; Jang MS; Chun S; Song GW; Park KT; Lee SG; Han DJ; Kang C; Cho DY; Kim JQ; Min WK
    Transplantation; 2009 Apr; 87(8):1225-31. PubMed ID: 19384171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Research progress regarding
    Jia Q; Ding Q; Shao K; Dang J; Zhang F
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Dec; 48(12):1874-1881. PubMed ID: 38448381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of cytochrome P450 family 3 subfamily A member 5 gene polymorphisms on daunorubicin metabolism and adverse reactions in patients with acute leukemia.
    Huang Z; Wang J; Qian J; Li Y; Xu Z; Chen M; Tong H
    Mol Med Rep; 2017 Jun; 15(6):3493-3498. PubMed ID: 28440407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liver Transplant Patient Carriers of Polymorphism Cyp3a5*1 Donors May Need More Doses of Tacrolimus From the First Month After Transplantation.
    Argudo A; González de Aledo JM; Alía P; Ramírez P; Serrano T; Fabregat J; Castellote J
    Transplant Proc; 2015 Oct; 47(8):2388-92. PubMed ID: 26518936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.